Edition:
United Kingdom

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
19 Jun 2018
Change (% chg)

$-0.01 (-1.75%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.58
Day's Low
$0.56
Volume
22,718
Avg. Vol
192,233
52-wk High
$1.47
52-wk Low
$0.29

Select another date:

Tue, May 22 2018

BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel

* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL

BRIEF-Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13

* ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING

BRIEF-Eyegate Announces $11.25 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK

BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology

* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment

* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:

BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln

* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:

BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery

* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY

BRIEF-Eyegate Promotes Sarah Romano To CFO

* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage:

Select another date: